"Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1." by John M. Pagel

Selected Works of John M. Pagel, MD, PhD

Article

Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.

Blood (2008)

John M. Pagel, Fred Hutchinson Cancer Research Center
Ted Gooley, Fred Hutchinson Cancer Research Center
Elihu Estey, Fred Hutchinson Cancer Research Center
Brent Wood, Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

November 16, 2008

Citation Information

John M. Pagel, Ted Gooley, Elihu Estey, Brent Wood, et al.. "Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1." Blood Vol. 112 Iss. 11 (2008) p. 3253 - 3253
Available at: http://works.bepress.com/john-pagel/216/